

## Speaker Biographies

### Adnan Abdul Jabbar

Associate Professor, Section Head Medical Oncology, The Aga Khan University, Pakistan



Dr. Adnan Abdul Jabbar is Section Head of Medical Oncology at one of the premier University Hospitals in Pakistan, The Aga Khan University. He is a graduate of Dow Medical College, Karachi and trained in Internal Medicine at the Nassau University Medical Center, New York and earned his Ph.D. in Immunology from RUSH University, Chicago, USA. Dr. Jabbar completed his Hematology/Oncology Fellowship from the Winship Cancer Institute, Emory

University, Atlanta, USA. He has served as the Chief Resident Department of Internal Medicine, Nassau University Medical Center, New York and then as Adjunct Clinical Assistant Professor Department of Medicine, New York College of Osteopathic Medicine of New York Institute of Technology, Chief Fellow Winship Cancer Institute, Emory University, Atlanta and as Assistant Professor, department of Oncology Aga Khan University, Karachi, Pakistan. Dr. Jabbar during his career is a recipient of numerous awards and grants. He serves on Boards of various committees and is currently the President Elect of the Society of Medical Oncology of Pakistan. He has several publications and poster presentations to his credit. He is Principle Investigator of many clinical trials and mentors post-graduate medical oncology trainees and supervises graduates for their Master's and PhD degrees.

### Ali Ünal

Haematology-Oncology Department, Erciyes University, Turkey



He is working at Erciyes University Haematology-Oncology department and Bone Marrow Transplantation Center, in Kayseri, Turkey. He received his MD degree at Erciyes University Medical School in Kayseri. He started his post graduated training in the department of Haematology at Ankara University İbni Sina Hospital and subsequently completed at the London University Royal Postgraduate School of Medicine Hammersmith Hospital.

His scientific training in Bone Marrow transplantation and cancer immunotherapy was gained at the Hebrew University Hadassah Medical School Bone Marrow Transplantation (Jerusalem, Israel). Ali Unal's main areas of research interests focus on: Haematological malignancy, Bone marrow transplantation, lymphoma, stem cell transplantation and therapeutic apheresis. His clinical research activities are mainly in the area of the lymphoma, leukaemia and tumour immunotherapy.

He was the president of Turkish Apheresis Society and member of, and Co-President of WAA 2012 Congress. He is member of National Haematology Association, European Society for Medical Oncology, American Society for Hematology and European Haematology Association.

He is serving on the editorial board of Turkish Haematology-Oncology Journal. He has published more than 200 scientific articles in international and national journals, peer-reviewed papers, review articles, book chapters, congress abstracts and oral presentations.

### Ahmad Ibrahim

Hematology/Oncology and Physiological Sciences, National Lebanese University, Lebanon



He is a full Professor of Medicine, Hematology/Oncology and Physiological Sciences at the Faculty of Medicine of the National Lebanese University, a Professor of Medicine at the Arab University of Beirut, an Associate Professor of Oncology at University of Paris XI, and Clinical Associate-Department of Internal Medicine at the American University of Beirut.

He graduated, from the University of Paris VII-School of Medicine in 1987. Then, he pursued a fellowship in Hematology/ Oncology, Immunology (HLA Lab, Professor Jean Dausset- Noble price of Medicine),

and Bone Marrow Transplantation at the University of Paris; then, a post fellowship in the department Bone Marrow Transplantation at Fred Hutchinson Cancer Center -Seattle, USA (Professor E.D. Thomas- Noble price of Medicine).

Doctor Ibrahim was appointed in 1993 as a full-time Attending Physician/Associate professor in the Department of Hematology and Bone Marrow Transplantation at the Institute Gustave Roussy (IGR)-Villejuif/ University of Paris XI. In 1997, he moved to Lebanon where he established the first Bone Marrow Transplantation Program at Makassed Hospital-Beirut which was affiliated with IGR/University of Paris XI in a French-Lebanese cooperation. Since 1997, Dr. Ibrahim has been the head of the Division of Hematology/Oncology and the Director of the Bone Marrow Transplantation Program at Makassed Hospital. Since 2004, he has been appointed associate director of research for PhD Programs at the Faculty of Pharmacy/University Paris V. Since 2012. He has been board member of Masters Programs in stem cell engineering and applications at the faculty of Sciences of the National Lebanese University. In 2018, Dr. Ibrahim was the coordinator of the guidelines for Hematological Diseases established for the Ministry of Public Health in Lebanon in cooperation of UNDP. Dr. Ibrahim is currently in advisor of International Clinical Practice Guidelines on the Treatment and Prophylaxis of Venous Thromboembolism in Patients with Cancer (ITAC-CME CPGS).

Dr. Ibrahim is actively involved in research particularly in the fields of hematological malignancies and hematopoietic stem cell transplantation. In 1993, he was nominated a core member of the European Organization for Research and Treatment of Cancer (EORTC)-Leukemias Cooperative Groups. In 1996, he was elected member of the French College of Hematology. Since 2009, he has been member of the Board of Directors of the Eastern Mediterranean Group for Blood and Bone Marrow Transplantation (EMBT). He is member of the American Society of Hematology (ASH), European School of Medical Oncology (ESMO), European Hematology Association (EHA), European Group for Blood and Marrow Transplantation/ Acute Leukemias and Lymphoma working parties (EBMT), and the American Society for Blood and Marrow Transplantation (ASBMT). Dr. Ibrahim is currently the President of the Lebanese Society of Hematology and Blood Transfusion, Key partner of the ASH and EHA. Dr. Ibrahim has taken an active role in the medical community-participating in numerous scientific meetings. He has authored and co-authored more than 300 medical publications and books chapters. He is also co-editor of a book in Hematology (edited in Paris-Maloine Publisher -1992).

In 1992, he received the Research Award of the Medical School of the University of Paris VII. In 1993, he received the award of the French League Against Cancer. In 2013, Dr. Ibrahim was awarded by the Lebanese Ministry of Health for his achievement in the field of hematopoietic stem cell transplantation in Lebanon. In 2018, he

received the award of achievement from the Pan Arab Hematology Association / EHA in Cairo, Egypt

#### **Alina Antipova**

*Hematology, N.N. Blokhin National Medical Research Center of Oncology, Russian Federation*



Alina Antipova has got her education Clinical Residence and Reserch fellowship in N.N Blokhin National Medical Research Center of Oncoogy. During her studies , she has become interested in hematology and continued her professional activity in the Department of Chemotheapy of Hemoblastosis. Her research interests are focused on the treatment patients with acute leukemias, myelodysplastic syndromes. Thus, she finished her PhD work on theme “Diagnos-

tic and treatment of rare types of acute leukemias”. Alina Antipova is participant of many conferences and grant winner.

#### **Angelo Maiolino**

*Internal Medicine and Hematology, Rio de Janeiro Federal University, Brazil*



Graduate in Medicine (1982), Universidade Federal do Estado do Rio de Janeiro  
Residence in Internal Medicine and Hematology (1986-88) at the University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro.

Fellow in Hematology and Bone Marrow Transplantation at the Hospital San Martino, Genova, Italy (1986-1988)

PhD in Internal Medicine - Hematology, Federal University of Rio de Janeiro (2000)

Professor of Medicine, Department of Internal Medicine, Federal University of Rio de Janeiro.

Chief of Hematology Service, Americas Centro de Oncologia Integrado, Rio de Janeiro

Member of the “International Myeloma Working Group”

#### **Carmino Antonio De Souza**

*Internal Medicine and Hematology and Hemotherapy, University of Campinas – São Paulo State, Brazil*



Professor Carmino Antonio De Souza graduated in Medicine in 1975, Medical Residency in Internal Medicine and Hematology and Hemotherapy 1976-1979, PhD in 1987, Free Professor in 1996 and Full Professor in 2001 of the Department of Internal Medicine of the Faculty of Medical Sciences - University of Campinas – São Paulo State - Brazil. He completed post-doctoral studies at the Department of Hematology, San Martino Hospital, University of Genoa, Italy, in 1997-1998. Onco hematologist,

working in the Malignant Lymphomas, Chronic Myeloid Leukemia and Bone Marrow Transplantation.

He has about of 365 published papers, mainly in English and Portuguese, more than 1200 abstracts in national and international congresses; 25 chapters of scientific books and 45 approved theses of master and doctorate degrees. H index - 58 and Hi10 index - 282 (Google Scholar – 20th July 2020).

He is member of the Hematology, Hemotherapy and Cell Therapy Brazilian Association, the American Society of Hematology

(ASH), the European Association of Hematology (EHA), the European Bone Marrow Transplant Group (EBMT) and founder member of LALNET (Latin America Leukemia Net) and AIBE (Brazilian Italian Association of Hematology). Head of the Hematology and Hemotherapy Center 1985 – 1993 and 2006 – 2011. São Paulo State Minister of Health – 1993 – 1994. Scientific Director of Brazilian Hematology and Hemotherapy Association (ABHH) – 2005-2009 and President of Brazilian Hematology and Hemotherapy Association (ABHH) – 2009-2013.

#### **Education and Training**

1970 - 1975 Graduation in Medicine at University of Campinas, São Paulo, Brazil

1976 - 1978 Medical Residency at University of Campinas – São Paulo –Internal Medicine and Hematology Department

1987 Doctoral Thesis at School of Medicine, Campinas-SP, UNICAMP

#### **Post Doctor Training**

1997 - 1998 University of Genoa – Italy – Ospedale San Martino – tutor - Dr. Gino Santini – Aggressive Malignant Lymphomas

#### **Charles A. Schiffer**

*Hematology & Oncology, Wayne State University, USA*



Charles A. Schiffer, MD, is Professor of Medicine and Oncology and the Joseph Dresner Chair for Hematologic Malignancies at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. He is the director of the Leukemia/Lymphoma Multidisciplinary Program.

Dr. Schiffer earned his BA cum laude at Brandeis University and his M.D. at New York University School of Medicine. He completed his internship, residency, and chief residency in Internal Medicine at Bellevue Hospital under the auspices of New York University School of Medicine and had subsequent training and positions at the Baltimore Cancer Research Institute, National Cancer Institute and the University of Maryland School of Medicine, where he served as Chief of the Division of Hematology. He has also served as Chief of the Division of Hematology/Oncology and Director of Clinical Research at the Karmanos Cancer Institute.

Dr. Schiffer has authored and co-authored more than 330 articles and 80 book chapters on topics concerning the treatment of leukemia in adults, platelet transfusion, and granulocyte transfusion therapy, among others. He has served on the Editorial Boards for Blood, the Journal of Clinical Oncology, International Journal of Hematology, Transfusion Medicine Reviews and Transfusion, and reviews articles for multiple journals. Committee memberships have included Chairman of the Leukemia Committee of the Cancer and Leukemia Group B, Chairman of the Food and Drug Administration Oncologic Drug Advisory Committee, member of the American Board of Internal Medicine – Medical Oncology Board, and grant reviews for the NCI, ASH, DOD, ASCO and Leukemia/Lymphoma Society of America. Dr. Schiffer has been named among Castle Connelly’s “Best Doctors in America,” and Newsweek’s “Best Cancer Specialists in the US.” In 2006, he received the Dr. John J. Kenney Award from the Leukemia/Lymphoma Society of America and the Celgene Award for Career Achievement in Hematology. He has received numerous teaching awards from the School of Medicine and was recently inducted into the Academy of Scholars of Wayne State University, the highest recognition accorded to academic faculty at the University.

**Christian Gisselbrecht**

*Hematology, Paris Diderot VII University Institut d'hématologie Hôpital Saint Louis, France*



Christian Gisselbrecht, MD is emeritus professor of hematology at Paris Diderot University VII at the Hôpital Saint Louis in Paris, France. He has been co-founder and president of the Groupe d'Etude des Lymphomes de l'Adulte (GELA), a French-Belgian cooperative group which has organized numerous randomized trials in lymphoma since 1984. GELA has extended its activities and changed its name to LYSA (Lymphoma Study Association). Dr Gisselbrecht has been lead investigator of several major phase II and phase III clinical trials, which investigated the place of autologous stem cell transplantation in the treatment of lymphoma. Currently, he is chair of the international CORAL study on relapsed diffuse large B-cell lymphoma. His research interests include clinico-pathologic correlative studies in lymphoma, the pharmacology of novel antineoplastic agents, and stem cell transplantation with a focus on relapses or poor prognosis lymphoma and T cell lymphoma.

Dr Gisselbrecht is an active member of several European and American scientific societies and is an expert with the European Medical Agency (EMA) as well as several cancer research agencies. He has published over 300 peer-reviewed papers and several book chapters and is on the editorial board of a number of highly respected journals.

**Dieter Hoelzer**

*Hematology, Onkologikum Frankfurt, Germany*



Dieter Hoelzer is Professor of Medicine and Hematology. His main research is Acute Leukemias. He founded the German Adult ALL Study Group (GMALL) which so far conducted 7 multicenter studies in >145 participating hospitals, where more than 7000 patients were treated.

Prof. Hoelzer was one of the five founders and President of the European Hematology Association (EHA), currently Vice President of the European and German Competence Network Leukemias and he also founded the European Working Group on Adult Acute Lymphoblastic Leukemia (EWALL). He currently chairs the Medical Advisory Board of the German Carreras Leukemia Foundation. Recently he was also the President of the Society for Hemato Oncology (SOHO). He is a member of the Medical Council and the Foundation Board of the DKMS (Deutsche Knochenmark Spender Datei).

Prof. Hoelzer received several awards for cancer research and therapy including those of the German Cancer Society, the "Deutsche Krebshilfe", the Johann-Georg-Zimmermann-Price, the San Salvatore Award and the European Leukemia Network Merit Award. He is a honorary member of the Hematological Societies of Austria, Hungary and Germany (DGHO) and received the doctor honoris causa from the University of Athens and First Pavlov State Medical University of Saint Petersburg.

Prof. Hoelzer is author or co-author of more than 800 peer-reviewed publications and co-author of international text books, such as Oxford textbook of Oncology and Harrison's principles of Internal Medicine 2018 and forthcoming 2020.

**Drew Provan**

*Hematology, The London School of Medicine and Dentistry, UK*



Drew Provan is Emeritus Reader in Autoimmune Haematology at Barts and The London School of Medicine and Dentistry in London, UK. He studied molecular genetics at Leicester University, UK before completing his medical degree. After junior medical posts in the UK, Dr Provan undertook research at The Dana-Farber Cancer Institute in Boston, USA on an American Travelling Fellowship awarded by the UK's Medical Research Council. He subsequently became a Consultant Haematologist at Southampton University NHS Trust before assuming his current position. Dr Provan's research interests include immune thrombocytopenia (ITP), neutropenia and haemolytic anaemia. He established the UK Adult ITP Registry, a clinical and laboratory database of patients with ITP for symptom recording, genetic analysis and remote monitoring, with the hope of establishing the underlying mechanisms leading to autoantibody production and identifying treatment response genes and surrogate markers. Along with international colleagues, Dr Provan published the consensus guidelines for the diagnosis and management of ITP in children and adults which is being updated and will be submitted early August 2019. He has written numerous peer-reviewed papers and book chapters, and has authored several medical books including Molecular Hematology, Oxford Handbook of Clinical Haematology, Oxford Handbook of Clinical and Laboratory Investigation, and ABC of Clinical Haematology.

**Eduardo M. Rego**

*Hematology, Faculty of Medicine of USP (FM-USP), Brazil*



Dr. Eduardo Rego graduated in Medicine from the Medical School of Ribeirão Preto - USP (FM-RP-USP) in 1988 and obtained his Ph.D. in Medicine (Clinical Medicine) from the University of São Paulo in 1997. He was a Post Doctoral Fellow at Memorial Sloan Kettering Cancer Center of New York (1998-2001). Upon returning to Brazil, he was nominated as Full Professor at FMRP-USP in 2010 where he worked until 2018. He is currently a Full Professor at

the Faculty of Medicine of USP (FM-USP) and coordinator of the Acute Leukemia Service of the Cancer Institute of the State of São Paulo (ICESP). He is the Coordinator of the Hematology Services of the D'Or Network (Oncology D'Or). His areas of interest is the hematological neoplasias, with special emphasis on the study of pathophysiology and the development of new treatment strategies for acute leukemias. Among his most cited works are: "Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RAR alpha and PLZF-RAR alpha oncoproteins" Proceedings of the National Academy of Sciences of the United States of America (2000); "Role of promyelocytic leukemia (PML) protein in tumor suppression" - Journal of Experimental Medicine (2001); "Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia" - Blood (2009) and "Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL" - Blood (2013). He is member of the Steering Committee and Coordinator in Brazil of the International Consortium of Acute Leukemias (ICAL) of the American Society of Hematology. The clinical studies developed by ICAL in Latin America aim to improve the outcomes of treatments for acute leukemias in the region and

promote the scientific advancement of hematology. Prof. Rego is the Chair of International Members Committee of the American Society of Hematology and Scientific Vice-Director of the Brazilian Association of Hematology and Hemotherapy (2018/2019). He is Editor of the Brazilian Journal of Medical and Biological Research; Deputy Editor of Hematology, Transfusion and Cell Therapy Journal (HTCT) and Associate Editor of the Annals of Hematology.

#### **Elias Jabbour**

*Leukemia, University of Texas MD Anderson Cancer Center (MDACC), Houston, USA*



Elias Jabbour, MD, is professor of medicine, Department of Leukemia, at The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas. He graduated from the Saint Joseph University School of Medicine, Beirut, and joined the Hotel Dieu de France University Hospital as a resident. He pursued a fellowship in hematology-oncology at the Gustave Roussy Institute, France. In 2003, he joined MDACC as a fellow in the Department of Hematology/Leukemia and Stem Cell Transplantation. He later joined the faculty in the Leukemia Department as assistant professor.

Dr Jabbour is actively involved in research in both acute and chronic forms of leukemia. He was involved in clinical trials that led to the approval of several drugs in chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). He actively assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. Dr Jabbour has designed more than a dozen clinical trials assessing new combinations for the management of de novo ALL, elderly ALL, and relapsed/refractory disease. Of note, he developed a protocol that has shown significant improvements in survival rates for patients with Philadelphia chromosome-positive ALL. In addition, he developed another innovative treatment approach for these patients by combining blinatumomab, a bispecific monoclonal antibody, with ponatinib, offering a chemotherapy-free regimen that it is hoped will further increase cure rates. Another area on which he focused his research is elderly patients with ALL. The aggressive biology of the disease and elderly patients' poor tolerance of intensive chemotherapy leads to low survival rates for this patient population.

Dr Jabbour is currently investigating an innovative strategy combining new monoclonal antibodies such as inotuzumab ozogamicin, a conjugated anti-CD22 antibody, and blinatumomab with minimal chemotherapy. If successful, such strategies will likely increase the cure rates of adult patients with ALL to the high level achieved in pediatric patients.

Dr Jabbour has taken an active role in the medical community, participating in numerous scientific meetings. He has authored or co-authored numerous publications (>550 peer-reviewed publications) and abstracts, and serves as a reviewer for many scientific journals. He has received several prestigious awards, among them merit awards from the American Society of Clinical Oncology (2005, 2006, 2007) and the American Society of Hematology (2005, 2006, 2007). He also received several other honors, including the Kimberly Patterson and Shannon Timmons fellowships and the highly coveted Celgene Future Leader in Hematology (2007) and Young Investigator in Hematology (2016) awards.

#### **Evangelos Terpos**

*Hematology, National & Kapodistrian University of Athens, School of Medicine, Greece*



Evangelos Terpos, MD, PhD is a Professor of Hematology and Director of Stem Cell Transplantation Unit in the Department of Clinical Therapeutics of the National & Kapodistrian University of Athens, School of Medicine, Athens, Greece.

His main research interest is the biology of plasma cell dyscrasias and especially the biology of bone disease in multiple myeloma.

Dr Terpos has evaluated the effect of bisphosphonates and different anti-myeloma therapies including ASCT, IMiDs-, proteasome inhibitor- and daratumumab-based regimens on bone metabolism. He has studied the biology and prevalence of osteonecrosis of the jaw in myeloma patients who receive bisphosphonates and denosumab as well as the role of modern imaging (including whole-body low-dose CT and DWI-MRI) for myeloma. He also studies the role of MRD in plasma cell neoplasms.

In the clinical research era, Dr Terpos participates in many important clinical trials with novel agents in the field of multiple myeloma and he is the PI in several real-world evidence studies with these novel agents. His research work was reported in more than 520 papers in peer-reviewed journals and Dr Terpos has more than 20,000 citations and an h-index of 70 in ISI/Web of Knowledge (July 2020).

Dr Terpos is co-chairing the Bone Subgroup of the International Myeloma Working Group and the Guideline Subgroup of the European Myeloma Network. Dr Terpos has given lectures at ASH, ASCO & EHA meetings, International Myeloma Workshops and in several national meetings. He is reviewer of scientific papers in more than 50 medical journals and has reviewed abstracts for ASH, EHA & EBMT meetings. He is Associate Editor of HemaSphere (official journal of EHA) for Myeloma and member of the Editorial Board of Haematologica and Blood Cancer Journal.

Dr Evangelos Terpos can be reached via e-mail at [eterpos@med.uoa.gr](mailto:eterpos@med.uoa.gr) and [eterpos@hotmail.com](mailto:eterpos@hotmail.com)

#### **Francesco Saglio**

*Hematology, AOU Città della Salute e della Scienza di Torino, Italy*



##### **Education**

MD Università degli Studi di Torino (Italy)  
2001- 2007  
Pediatrics Università degli Studi di Torino (Italy) 2009-2014  
Post-doctoral Fellowship Baylor College of Medicine, TX, US 2011-2012  
PhD Biomedical Sciences & Oncology Università degli Studi di Torino (Italy) 2014- 2018

##### **Professional Experiences**

2014 - 2015 Part-time Attending Physician Pediatric Emergency Room, AOU Città della Salute e della Scienza di Torino, Turin, Italy  
2015 - 2017 Attending Physician Pediatric Onco-Hematology, Cell Therapy and Stem Cell Transplantation Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy  
2017- now Full-time position Attending Physician Pediatric Onco-Hematology, Cell Therapy and Stem Cell Transplantation Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy

##### **Main areas of interest**

Main areas of interest are the immunological aspects of hematopoietic stem cell transplantation in the pediatric population especially in relation to the opportunity to generate virus and leukemia directed cytotoxic T cell lines to be used in adoptive cell therapy

protocols. Experience in translational research and in the management of GCP compliant phase I-II and III clinical trials.

### Giuseppe Saglio

Hematology, University of Torino and Ospedale Mauriziano, Italy



Giuseppe Saglio is a Professor of Internal Medicine and Haematology at the University of Turin. He is Director of the Department of Clinical and Biological Sciences at the San Luigi University Hospital, Director of the Division of Hematology of the Mauriziano Hospital in Turin and Coordinator of the PhD programme in Molecular Medicine.

Chronic Myeloid Leukemia (CML) is likely to represent in modern medicine the most successful achievement of the so called targeted therapy and precision medicine. Since the discovery of the Philadelphia chromosome and of its closer association with this specific disease, a continuous flow of biological and clinical research has progressively provided insights on the CML pathogenesis and on mechanisms leading to its progression to an acute phase, that until two decades ago was the major cause of death for the CML patients. This situation totally changed since the introduction of imatinib, the first tyrosine kinase inhibitor (TKI) introduced in clinical medicine. Several studies indeed suggest that after 10 years from the start of therapy, the OS of the CML patients is almost overlapping that of a control population without leukemia. These results however are not only due to imatinib, but also to other TKIs of second and third generation like nilotinib, dasatinib, bosutinib, radotinib, ponatinib and others. These TKIs are generally used as second or third line treatment in cases (approximately 35-40% of all patients) who are intolerant or resistant to imatinib therapy, but nilotinib, dasatinib and bosutinib have been used and registered also as first line therapy in the attempt to improve the first-line therapy results that can be obtained with imatinib. The decision to change therapy is based on the molecular quantification by quantitative RQ PCR of the amount of the BCR/ABL transcript at specific time points that is corresponding to the amount of the residual disease. The selection of the TKI to be used as first or second line therapy is also in many cases established based on the profile of the BCR-ABL mutation present. In other cases is the toxicity profile of each TKI the factor determinant for the choice. The enormous success of the TKI therapy however should not overshadow the fact that most of them are bound to continue the TKI therapy for the rest of their life. Therefore the new frontier of the CML therapy is represented by the treatment free remission (TFR) that means that the patient can discontinue the TKI therapy without experiencing a relapse of the disease. This in the next year will certainly represent a new challenge in which the so called precision medicine will play a major role.

### Guillermo Garcia-Manero

Leukemia, Texas MD Anderson Cancer Center, USA



Guillermo Garcia-Manero is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. He also serves as the Chief of the Section of Myelodysplastic Syndromes, Vice Chairman for Translational Research, Leader of the AML/MDS Moon Shot Program and Program Director of the Leukemia Fellowship Program (September 2019). He recently was elected as Chair-elect of the Faculty

Senate of the University of Texas MD Anderson Cancer Center, which also starts in September 2019.

Dr. Garcia-Manero was born in Spain and received his medi-

cal degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, UK. From 1993-1996, he performed his internship and residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, PA. He then continued his training with a fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, also at Thomas Jefferson University Hospital, where he served as chief fellow. In 1999, he became Assistant Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center where he has remained for the rest of his academic career.

Dr. Garcia-Manero focuses on the understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for patients with these disorders. His work has been funded by NIH, DoD, LLS, CPRIT, and the MDS/AML Moon Shot project. He has co-authored over 682 manuscripts. His last H-index is 119 and his i10-Index is 630 with over 58,000 citations to his work. Currently, he is PI or Co-PI on over 25 active clinical trials focusing on AML and MDS. He directs what is likely the largest single institution unit for patients with MDS in the world, with over 400 patients referred annually, and maintains one of the busiest clinics at MD Anderson. The Section of MDS is comprised of leukemia faculty dedicated to care for patients with MDS and two research laboratories directed by Dr. Colla and Dr. Wei. In addition, the section coordinates the work of over 15 research nurses. Dr. Garcia-Manero has received a number of significant awards, such as The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research at MD Anderson. He has also been recognized as one of the Best Doctors in America each year since 2007. He has trained over 100 fellows and post doctoral fellows and has been a speaker at multiple national and international forums.

### Giovanni Martinelli

Scientific Director, Istituto Scientifico romagnolo per lo Studio e la cura dei Tumori (IRST) – IRCC, Italy



#### Education

Degree in Medicine at Verona University in 1985  
Residency in Hematology at Verona University in 1988  
Residency in Medical Genetics at Verona University in 1992

#### Careers

Scientific Director of Hematology Unit at Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, Italy (2018-today)

Medical doctor at University of Bologna Institute of Hematology “L. E. A. Seràgnoli”, Italy (1993-2001)

Professor at Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy (2001-2017)

#### Achievements

Responsible of the individual program - “Diagnosis and treatment of acute leukemias and myelodysplastic syndromes” Sant’ Orsola Hospital, Bologna.

Was the coordinator of Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (NGS-PTL) Eu-funded project Winner of 2016 Investigator Grant, AIRC, Associazione Italiana per la Ricerca sul Cancro

WP LEADER (2017), IMI2 consortium “healthcare alliance for resourceful medicines offensive against neoplasms in hematology”

WP LEADER of H2020 project ONCORELIEF

WP LEADER of Erapermed Project SYNThERAPY

**Irina Poddubnaya***Hematology, Russian Society of Oncohematology, Russian Federation*

Ph. D., Professor, Vice-rector for Educational Work and International Cooperation, Head of Oncology and Palliative Medicine Chair, Russian Medical Academy for Continual Professional Education of Russian Ministry of Health. Since 1974 she works in Russian Medical Academy for Continual Professional Education (RMACPE) as assistant lecturer, associate professor, professor, and since 1989-Head of department. In 2003 she was appointed as a vice-rector RMACPE. Prof. Poddubnaya since 2005 is a corresponding Member and since 2014 is Academician of Russian Academy of Sciens.

Her main sphere of scientific interests includes all aspects of diagnosis and treatment of malignant lymphoproliferative disorders and different forms of solid tumors; her activities include scientific clinical research, teaching and lecturing, as well as developing international scientific cooperation projects.

In 1994 she received the ESSO Sekiyu Kabushiki Kaisha Research grant (Japan) for her Research "Study of different features of nodal and extranodal non-Hodgkin adult lymphomas and development of effective treatment". In 2002 prof. Poddubnaya was awarded as a Honorary Educational Worker of Russia.

In 1999-2002 she was a member of Annal Oncology Editorial Board as a member of the ESMO Publishing Working Group. She is Editor-in-Chief of quarterly Russian journal "Contemporary Oncology" since 1999. 2012-2016 she was Editot-in-Chief of Russian edition of Journal of Clinical Oncology (ASCO) She is the organizer and chair of annual Russian Conference with International Participation "Malignant Lymphomas". Since 2011 she is president of Russian Society of Oncohematologists".

Prof. Poddubnaya actively participates in numerous International and Russian clinical trials as principal investigator or co-investigator. She is author more than 550 articles, 8 monographies, chapters in manuals. Since 2012 she is editor-in-chief of Russian National Clinical Recommendations on Diagnostics and Treatment of Lymphoproliferative Diseases (in 2018 - the 4-th edition).

**Jean François Rossi***Hematology, University of Montpellier, France*

Jean-François Rossi University of Montpellier He is professor of Hematology at the University of Montpellier. He has over 30 years of experience in medicine and was certified in Rhumatology, Medical Oncology, Hematology, Immunology and Internal Medicine. He received his MD and PhD degrees in Hematology Immunology at the University of Montpellier and had post-doc at the Universities of Arizona (Tucson) and San Antonio (Texas) for multiple myeloma and bone research. He was

associate professor at the University of Suzhou (China) for more than 10 years. He is member of 7 international scientific societies and the Scientific Advisory Board of the Castleman Disease Collaborative Network (CDCN). He was in charge of Medical Oncology for 5 years in Montpellier Cancer Center. He became the head of the Hematology Department during 14 years and he developed with Professor Bernard Klein the Biotherapy Saint-Eloi site (Immunotherapy/Regenerative Medicine (Chu/Inserm/University)). He is particularly active in Immunotherapy for cancer and programs on crossed information analysis for algorithms including epigenetics with microbiota with 198 PubMed publications and 4 patents. He participated or activated different clinical or bio-clinical research programs with pharmaceutical companies (more than 150) or with academic institutes. He obtained an Award from the Ameri-

can Association for Cancer Research on April 2017 for his work on inflammatory process and interleukin 6 (<http://aacrjournals.org/content/j-f-rossi-bio> and The Best of the AACR Journals). He was a consultant for different for more than 20 years, in the domain of immune precision medicine and the development of different drugs, notably siltuximax (Centocor, EUSAPARMA) TACI-Ig (Serono Merck), IPH1101 (Innate Pharma), anti-CD20 LFB-R603 (LFB), polyoxidinium (Petrovax Pharm LLC), POC for Horiba Medical, and for Marc Cluzel, Sanofi Research. He participated to the creation of 4 start-ups. He is an active member of the Scientific Advisory Boards for 3 start-ups such as Urodelia and Beta Innov. With E-Sana as a co-founder with Pr Kalle Levon (Polytechnic Institute of NYU, Brooklyn, USA) and Césaire Massart, he participates to new programs based on innovative technology for tests including in-Home and biological monitoring, with dynamic follow-up. Nowadays, he develops a new Institute For Precision Medicine and Immunotherapy at the Cancer Institute Sainte Catherine, Avignon, France, with the collaboration of LABOSUD/INOVIE, academic labs (linked to the University Hospital in Montpellier and the Institute Paoli-Calmette, in Marseille) and start-ups. This platform integrates an international scientific committee and will use new technologies in Telemedicine.

**Joseph (Yossi) Schwartz***Transfusion Medicine & Cellular Therapy Service, Columbia University, USA*

Joseph (Yossi) Schwartz is a Professor of Pathology and Cell Biology at the Vagelos College of Physician and Surgeons of Columbia University and the Director of the Transfusion Medicine & Cellular Therapy Service at the Columbia University Irving Medical Center campus of the New York Presbyterian Hospital. As the Director of the Transfusion Medicine & Cellular Therapy Service, Dr. Schwartz oversees the Blood Bank, The Apheresis unit

and the Cell Therapy facility. As a major tertiary & transplantation center, those facilities collect, receive & process blood products for transfusion in variety of indications such as patients with Sickle Cell Disease, complex cardiac surgery, Hematopoietic Progenitor Cell transplantation, and all types of solid organ transplantation. He was until recently the chair of the FACT-JACIE international standards for cellular therapy and just finished his term as he Immediate Past-President of the American Society for Apheresis (ASFA). He was part of the writing committee in the last 5 editions of ASFA's special issue published every 3 years describing current evidence-based clinical applications of Therapeutic Apheresis.

**Kinuko Mitani***Hematology, Dokkyo Medical University, Japan*

Kinuko Mitani, MD & PhD, is Chair and Professor of the Department of Hematology and Oncology at Dokkyo Medical University in Tochigi, Japan. She graduated from the University of Tokyo in 1984. Thereafter, she received a postdoctoral training at her home institute and at The Rockefeller University in NY until 1994. She joined Dokkyo Medical University as a professor of medicine in 2000. She has cloned a leukemia-causing gene, RUNX1-EVI1,

and analysed its functions in vitro and in vivo. Currently, Professor Mitani is a vice president of the Japanese Society of Hematology and is a secretary general in the Asian-Pacific division of International Society of Hematology.

E-mail address: Kinukom-tky@umin.ac.jp

**Kirill Lepik***Hematology, Pavlov University, Russian Federation*

Kirill Lepik completed residency in hematology in Pavlov University in 2016 and PhD program in 2019. His PhD work was related to the implementation of immune checkpoint inhibitors in the treatment of classical Hodgkin lymphoma. During last several years he actively participated in several research projects in Pavlov University including the optimization of immunotherapy strategy in resistant lymphomas, analysis of the mechanisms of resistance to PD-1 inhibition in Hodgkin lymphoma, approaches of immune checkpoint inhibitors combinations as a bridge to allogeneic hematopoietic stem cells transplantation. His research was presented at the EHA, EBMT and ASH meetings.

**Koichi Akashi***Hematology, Kyushu University, Japan*

1985 Graduated from Faculty of Medicine, Kyushu Univ.  
 1985 Resident, and Research Fellow, First Department of Internal Medicine, Kyushu Univ.  
 1994 Postdoctoral Fellow, Department of Pathology, Stanford Univ. School of Medicine, (Irving L. Weissman's lab)  
 2000 Associate Professor, Dept. of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School  
 Professor and Chair, Department of Medicine and Biosystemic Science, Kyushu University, JAPAN

2008-present

**Marcio Nucci***Hematology, Medicine at Rio de Janeiro Federal University, Brazil*

He is Professor of Medicine at Federal University of Rio de Janeiro, Brazil, and has been responsible for the Program of Infection in the Hematology and Bone Marrow Transplantation unit at the University Hospital for over 25 years. He has received his medical degree in 1981 from the Federal University of Rio de Janeiro State, has completed his residency in Hematology at Federal University of Rio de Janeiro in 1985 and has trained in Infectious Diseases at Università la Sapienza, Roma, Italy in 1991. Dr. Nucci is also consultant in Infectious complications of cancer and bone marrow transplantation in two hospitals, working in a telehealth platform.

His clinical and research interests include the epidemiology, diagnosis and management of invasive fungal diseases in immunocompromised hosts and infectious complications in hematologic patients and hematopoietic cell transplant recipients. Marcio Nucci has published over 200 peer-reviewed articles, and has been speaker in several medical conferences. He is member of the American Society of Hematology and of the European Confederation of Medical Mycology. He is past member of the Immunocompromised Host Society Council and the Mycosis Study Group Steering and Educational Committees, and is a reviewer of various medical scientific journals.

**Martin H. Ellis***Hematology, Tel Aviv University, Israel*

Professor Ellis is the head of the Hematology Institute and Blood Bank at the Meir Medical Center and is Associate Professor of Hematology at the Tel Aviv University. He is also the Chairman-elect of the Israel Society of Hematology. He was the founding chairman of the Israel Myeloproliferative Neoplasms (MPN) Working Group and currently heads the Israel MPN Registry.

Prof Ellis is a member of the MPN working groups of the European Leukemia Network and the European Hematology Association.

Prof. Ellis's clinical and research interests are the pathophysiology of MPN-related thrombosis and its treatment as well as anticoagulant therapy for thrombotic diseases.

He has published numerous papers focused on the current management of MPNs and using meta-data, has demonstrated in a "real-world" context the importance of appropriate dosing of the direct oral anticoagulants.

He has performed a number of national and international studies of JAK inhibitor treatment for myelofibrosis and of the treatment of thrombotic complications of the myeloproliferative neoplasms.

**Mehmet Yilmaz***Hematology, Sanko University, Turkey*

Mehmet Yilmaz, MD is a Professor of Internal Medicine Department of Hematology in SANKO University School of Medicine, Gaziantep. He was graduated from Cukurova University School of Medicine. Post graduate training; Internal Medicine and Hematology 1995-2002 Ankara Numune Education and Research Hospital, Immunohematology, Therapeutic Apheresis and blood transfusion as observer Leiden Medical Center 2007, Therapeutic Apheresis and Clinical Education of

Blood and Bone Marrow Transplantation 2008, Erciyes University Department of Hematology Bone Marrow transplant and Therapeutic Apheresis Center, Kayseri. He founded hematology discipline at 2004, therapeutic apheresis center 2010 as a chief and bone marrow transplant as vice-chairman in Gaziantep University School of Medicine at 2009. His main research interest is hematologic malignancies and therapeutic apheresis. In clinical research era Dr. Yilmaz participated some important clinical trials (deferasirox, Rituximab, The World CML Registry, Bosutinib, SC Rituximab, Obinituzumab) on the fields hematologic malignancies. Dr. Yilmaz has written over the 200 publications, abstracts and other scientific presentations. Throughout his career had received numerous national abstract awards. Dr. Yilmaz is member of several professional, national and international scientific societies including EHA, EHO, Turkish Society of Hematology, Experimental Hematology and Turkish Society of Apheresis.

**Mustafa Cetiner***Hematology, Acibadem Maslak Hospital, Turkey*

He was born in Kayseri in 1964. He received his MD degree at Ankara University School of Medicine in 1988. He pursued his career at the Department of Hematology in Marmara University Faculty of Medicine as a fellow, an attending physician and an associated professor respectively. He participated in research projects of the Hematopoietic Stem Cell Transplant Program in Northwestern University Robert Lurie Cancer Center, Chicago, US as a visiting scholar between 2004 and 2005 for 6 months.

He established Bone Marrow Transplantation Program in Sisli Memorial Hospital and became a director in 2011-2012.

Dr. Cetiner was a professor of the Hematology Department at Koc University School of Medicine between years of 2013 and 2018. He served as a founder and head of the Internal Medicine Department at Koc University School of Medicine in 2015-2018. He worked at the Hematology Department of V.K.V. American Hospital from 2008 to 2019.

He has been working as an official doctor of "United Nations" since 2010.

He is an active member of several national and international medical societies including Turkish Medical Association, the Turkish Society of Hematology, American Society of Hematology, European Hematology Association and MDS Foundation.

He has been a co-chairman of the recognized international meeting "New Trends in Hematology" organized in Istanbul since 2007. Besides his academic career, Dr. Cetiner remarkably contributes to social responsibility projects. He is among the founders of "Cancer Warriors" in Turkey that is dedicated to providing care and support for cancer patients and their families.

He has an extensive and prominent career as an author. He has published over 50 articles in peer-reviewed scientific national and international journals also 3 books about hematological malignancies. Besides, he has also 3 popular science books titled "To Your Health", "Portraits from the History of Lymphoma" and "The Milestones in the History of Hematology".

He published over 500 columns under the title of "Actual Medicine" in national "Cumhuriyet (Republic) Newspaper" for 10 years till 2017. Currently, he continues to write his columns in weekly "Science and Technology Magazine".

He is currently working at the Hematology Department of Acibadem Maslak Hospital.

#### **Naeem Arshad Chaudhri**

*Hematology, King Faisal Specialist Hospital & Research Centre, Saudi Arabia*



College of Medicine, Alfaisal University Director, Research Unit, Oncology Centre Consultant, Adult Hematology/HSCT King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia

Dr. Chaudhri is a Consultant in Hematology and Hematopoietic Stem Cell Transplantation at KFSH&RC. He is board certified in Internal Medicine, Medical Oncology and Hematology from American Board of Internal Medicine and he completed his fellowship in Hematology and Medical Oncology in 1995 at Lombardi Cancer Center, Georgetown University Hospital, Washington D. C. He joined King Faisal Specialist Hospital and Research Centre in 1996. KFSH&RC is the major tertiary care referral centre in Saudi Arabia and Middle East with Oncology Centre being accredited by the World Health Organization (WHO) as a Collaborating Centre for Cancer Prevention and Control.

His main interest is Malignant Hematology, specifically Acute and Chronic Leukemia as well as Hematopoietic Stem Cell Transplant.

Dr. Chaudhri is also the Director/Head of Research Unit overseeing clinical research in the Oncology Centre at KFSH&RC. He is the principal investigator of the South West Oncology Group (SWOG) for KFSH&RC and principal investigator of numerous ongoing clinical trials. He is an Associate Editor-in-chief of Annals of Saudi Medicine and an Editorial Board of other journals. He has around 130-140 publications and abstracts in peer-reviewed journals.

At the same time, Dr. Chaudhri is the Congress Chairman of the annual conference of the Critical Reviews in Hematological Malignancies in Riyadh, Saudi Arabia and also a member of organizing and scientific committees of numerous national and international meetings. He is invited speaker on national and international scientific meetings.

#### **Nancy M. Dunbar**

*Hematology, Dartmouth-Hitchcock Medical Center, USA*



Nancy M. Dunbar, MD is an Associate Professor of Pathology and Laboratory Medicine and of Medicine at the Geisel School of Medicine at Dartmouth. She serves as the Medical Director of the Blood Bank and the Associate Medical Director of the Transfusion Medicine Service at Dartmouth-Hitchcock Medical Center. She currently serves as co-chair of the American Society for Apheresis (ASFA) Journal of Clinical Apheresis Special Issue Writing Committee and edited the most recent issue

"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: Evidence-Based Approach" published in June 2019. These guidelines are widely used by healthcare personnel and provide the current level of evidence and strength of the recommendation for the use of apheresis in human disease.

#### **Ozan Salim**

*Hematology, Akdeniz University School of Medicine, Turkey*



Ozan Salim, MD is an associate professor of hematology at Akdeniz University Hospital in Antalya, Turkey.

#### *Education*

Fellow - Hematology: Akdeniz University School of Medicine  
Resident - Internal Medicine: Istanbul University Cerrahpasa School of Medicine  
Medical School, Internship: Istanbul University Cerrahpasa School of Medicine

#### *Professional details*

Member, Turkish Society of Hematology (TSH)  
Member, European Hematology Association (EHA)  
Lymphoma master class graduate organized by the TSH, 2017  
Secretary of the lymphoma scientific subcommittee of TSH, 2018  
- present  
Chief, Hematology Department, Akdeniz University Hospital, 2012 - 2018  
Director, Special Hematology Laboratory, Akdeniz University Hospital, 2012 - present  
Director, Blood Bank, Akdeniz University Hospital, 2012-2013.

#### *Publications*

Author of approximately 30 published articles on hematologic subjects.

#### *Personal details*

Dr. Ozan Salim has a particular interest in non-Hodgkin's and Hodgkin's lymphoma. He has been involved in writing lymphoma guideline for TSH. He lives in Antalya with his wife and son. He likes fishing, playing football and swimming.

#### **Panayiotis Panayiotidis**

*Hematology, National and Kapodistrian University of (NKUA), Greece*



-Graduated from the Medical School of University of Athens in 1982.

-Trained in Haematology in the 1<sup>st</sup> Department of Internal Medicine, University of Athens (Head prof Faidon Fessas).

-Diploma in Haematology 1992

- Post graduate studies:

a) Karolinska Hospital, Stockholm, Hematology Clinic (Head Prof Peter Reisen-tain)1984-1985.

b) Royal Free Hospital, London, Haematology Clinic (Head Prof Victor Hoffbrand, 1992- 1996) as an ESMO fellow and Hon. Lecturer.  
-Present Position: from 1996- present : National and Kapodistrian University of (NKUA) Athens, 1<sup>st</sup> Department of Propaedeutic Medicine, Laikon General Hospital, professor of Haematology

Head of the Haematology Research Laboratory, NKUA

-Member of the ERIC and IG-CLL groups., of ELN.  
-Member of the EUTOS committee “path to cure group in CML” of the ELN  
-National representative for Greece in the EUTOS CML European Group of ELN.  
-Member of the Steering Committee of the EURO-SKI trial of ELN.  
-Member of Hellenic Society of Haematology (President 2007-2018)  
-President of the Educational committee of the Hellenic Society of Haematology (2018-2020)  
-158 publications in neoplastic hematologic diseases with >6000 citations

### Rajko Kusec

Consultant Hematologist, Dubrava University Hospital, Croatia



I was born and I practice hematology in Zagreb, the capital of Croatia, a historical, today modern and vibrant city that celebrated its 900th birthday recently. My parents were chemists, but I think I knew relatively early that I was going to study medicine. So, I did, at Zagreb University and after finishing my residence and fellowship in internal medicine I left to Vienna for postgraduate study in hematology at Medical university, department of hematology and hemostaseology. This was very important

experience where, besides the clinic, I was introduced to molecular hematology, something which is part of my professional activity in form of molecular diagnostics today. Another important and interesting aspect of understanding hematological disorders, particularly neoplasms, was opened to me at University of Oxford at Haematology research unit of Nuffield department of medicine. Hunting for candidate tumour suppressor gene(s) in the deleted region of long arm of chromosome 5 in MDS was a unique perspective for a clinician! I eventually returned home and since then I am active as clinical hematologist that also supervises molecular hematology diagnostics at University hospital Dubrava and, as professor of internal medicine at Zagreb School of medicine, I teach undergraduate and postgraduate students. When thinking of myself as a physician, medical professional and a person who had opportunity to experience different but complementary levels of hematology I can say that through all this I became more aware of the challenges and complexity of blood diseases. Through this unique “journey” I had privilege to encounter many interesting people, made many true and lasting friendships and also retained international connections resulting in collaborations and projects in hematology, particularly in myeloid neoplasms. Through my “case “. I may suggest that it is visible that interconnecting, exchanging ideas and experiences, will move us all forward in our mission of being better doctors for our patients!

### Robert Peter Gale

Hematology, UCLA, USA



He was born in New York in 1945 where he attended Erasmus Hall Academy and the Pratt Art Institute studying industrial design. He received his AB with high honors in biology and chemistry from Hobart College in 1966, MD from the State University of New York at Buffalo in 1970 and PhD in microbiology and immunology from the University of California, Los Angeles (UCLA) in 1976). His postgraduate training was at UCLA 1970-74. 1983-4 he

was the Meyerhoff Visiting Scholar at the Weizmann Institute of Science in molecular biology. From 1973-1993, Gale was on the faculty of the UCLA School of Medicine and remains on the UCLA Ronald Regan Medical Center Staff.

From 1980-1997, Gale was Chairman of the Scientific Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), 1989-2003 he chaired the Scientific Advisory Board of the Center for Advanced Studies in Leukemia. From 1986-1993, he was President of the Armand Hammer Center for Advanced Studies in Nuclear Energy and Health, and 1985-1990 he was the Wald Scholar in Biomedical Communications at UCLA. Gale is currently Visiting Professor of Haematology at the Haematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London and Honorary Professor of Hematology at the Institute of Hematology at Peking Union Medical College. He is the Editor-in-Chief of LEUKEMIA, Associate Editor of CLINICAL TRANSPLANTATION, Executive Editor of BONE MARROW TRANSPLANTATION and a reviewer for many scientific journals in hematology, oncology, immunology, transplantation, radiation biology and internal medicine. Prof. Gale is also an expert on the medical response to nuclear and radiation accidents. From 2007-2019 he was executive director of clinical research and development at Celgene Corp and an honorary member of the Russian and Chinese Academies of Medical Science.

Gale has published over 1,100 scientific articles and 25 books on medical topics, nuclear energy and weapons and politics of US-Russian relations with articles for the New York Times, Los Angeles Times, Washington Post, USA Today, Der Spiegel, the Wall Street Journal and others. Dr. Gale has also written popular books on Chernobyl and US nuclear energy policy and screenplays for and/or appeared in several movies and received an Emmy award. His latest book “Radiation: What it is, What you need to know” was published in 2013 by A. Knopf.

Awards for his scientific achievements include the Presidential Award, New York Academy of Sciences, Scientist of Distinction Award, Weizmann Institute of Science, Distinguished Alumni Award, Hobart College and Intra-Science Research Foundation Award. He holds honorary degrees including DSc from Albany Medical College, LHD from Hobart College and DPS from MacMurray College.

### Robin Foà

Hematology, Sapienza’ University, Italy



Professor of Hematology, ‘Sapienza’ University of Rome. He earned his medical degree in Turin, Italy, and specialized in pediatrics and in hematology. Worked at the MRC Leukaemia Unit, Hammersmith Hospital, London between 1976 and 1979. Sabbatical at Memorial Sloan-Kettering Cancer Center, New York, between 1991 and 1992.

He is part of the European Leukemia Network and referee for national and international funding agencies.

Chairman of the Scientific Committee of the 4th EHA Congress, Barcelona 1999, councilor of EHA until December 2002, and member of the Education Committee of EHA until December 2005. President-Elect, President and Past-President of EHA during the years 2007-2013.

Chairman Education Committee and Outreach Unit of EHA up to June 2017.

Member of EHA’s Global Outreach Committee.

Chairman of the GIMEMA Working Party for chronic lymphoproliferative disorders, and member of

the board of the Working Party for acute leukemias.

Has authored over 750 papers, reviews and books. Has been co-editor of Leukemia and Lymphoma, and associate editor of the British Journal of Hematology and of The Hematology Journal. Editor-in-chief of The Hematology Journal up to December 2004 and of Haematologica from January 2005 to February 2008.

**Rodrigo T. Calado***Hematology, University of Sao Paulo, Brazil*


Dr. Rodrigo T. Calado received his MD in 1997 and his PhD in 2003 both from the University of Sao Paulo, Brazil. He received his postdoctoral training in hematology at the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, where he also worked as Staff Scientist. His main research focus is in hematopoietic stem cell failure, including inherited and acquired aplastic anemia. Dr. Calado has helped to characterize the molecular genetics of telomeroopathies and acquired aplastic anemia and developed novel therapies for these disorders.

He is currently Scientific Director of the Ribeirao Preto Blood Bank, and Head of the Hematology Laboratory, University of Sao Paulo, Brazil.

**Rüdiger Hehlmann***Hematology, Germany*

Prof. Dr. med. Dr. h. c. Rüdiger Hehlmann, chief of medicine at the Mannheim Medical Faculty of Heidelberg University until 2007. Founder and chair of the German CML Study Group 1982-2017, the German Competence Network for Acute and Chronic Leukemias 1997 to present, and the European LeukemiaNet (ELN) 2002 to present. Past president of the German Society of Hematology and Oncology, past Dean of his faculty and past Secretary General of the International Association of Comparative Research on Leukemia and Related Diseases (IACRLRD). He is honorary member of the Polish and German Societies for Hematology and Oncology. His focus is fostering cooperative research for curing leukemia.

Selected publications  
Hehlmann R. Review: Chronic myeloid Leukemia in 2020. *HemaSphere* 2020, in press  
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley J, .....  
Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia* 2020; 34: 966-984  
Hehlmann R. Advancing a field by building consortia: The example of the European LeukemiaNet. *Cancer*. 2018 Mar 15;124(6):1100-1104.  
Khoury HJ, Williams LA, Atallah E, Hehlmann R. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. *Am Soc Clin Oncol Educ Book*. 2017; 37:468-479.

**Salam Alkindi***Hematology, Sultan Qaboos university, Oman*

Following my graduation from Trinity college-Dublin Ireland, in 1993, I have completed my general medicine as well as haematology/oncology training in Dublin, Ireland as well as the Fred Hutch cancer centre in Seattle USA, where I did my training in Bone marrow transplant. In 1999 I have joined Sultan Qaboos University and in 2005 I was appointed as head of department of haematology for 10 years. Previously also I held the position of deputy director of Sultan Qaboos university

hospital for clinical affairs (clinical director in effect) for about 5 years. Research interests include sickle cell disease, chronic leu-

kaemia and autoimmune disorders with over 100 articles published in international peer reviewed journals.

**Tariq I. Mughal***Hematology/Oncology, Imperial College London, UK*

Tariq trained in medicine at St George's Hospital in London, followed by postgraduate training at Imperial College London at the Hammersmith Hospital, London, and the University of Colorado School of Medicine, Denver. He has specialist credentials in internal medicine, medical oncology, hematology, and stem cell transplantation in the UK and USA. He has held senior clinical leadership roles in centers of excellence for the treatment of

cancer, as well as positions of increasing seniority in pharmaceutical medicine, focusing on the interface between academia, clinical practice and industry. He is involved in humanitarian activities to co-ordinate cancer care in Africa since 2011, when he founded Alpine Oncology Foundation, a Swiss-registered cancer charity, in memory of his mother, with the principal objective to help improve the clinical management of children and adults in Tanzania diagnosed to have blood cancer by enhancing the understanding of these diseases and promoting access to affordable molecular diagnostic and monitoring tools. He has published over 130 peer reviewed papers, 30 cancer text book chapters and 13 cancer books. He is the recipient of several awards, including those from the UK Royal College of Physicians, American College of Physicians, Swiss humanitarian groups and runner-up for the Highly Commendable British Medical Association (UK) Book Award.

**Tomasz Sacha***Hematology, Jagiellonian University, Poland*

Ass. Prof. Tomasz Sacha MD.PhD. graduated from the Medical Academy in Kraków in 1992. During his studies, he worked actively in the research team at the Department of Internal Medicine in Kraków and won twice the prize of the Students' Scientific Society competition for the best scientific project. He worked as an assistant in the Haematology Department at the Jagiellonian University in Kraków after initial specialization in internal medicine. He specialized further in haematology after several pieces of training in Basel, Genoa and Turin, and became a lecturer and professor at the Jagiellonian University in Kraków. He received his PhD for his work on molecular diagnostics of Chronic Myeloid Leukemia (CML). In 2008, he completed his specialization in laboratory diagnostics and, in 2013, he habilitated at the Jagiellonian University. Dr Sacha established a National Molecular Reference Laboratory for quantitative BCR/ABL analysis and is responsible for the standardization of this procedure in Polish Molecular Laboratories. In 2002 he contributed to the organization of Polish Advocacy Group of patients suffering from chronic myeloid leukaemia. For his activity, he was awarded the prize: "Service for Life Award" and became an Honorary Member No 1 of this Society.

Since 2013, he is a president of the Molecular Hematology Section of the Polish Society of Human Genetics, and since 2017 he is the president of Chronic Myeloid Leukemia Section of the Polish Adult Leukemia Group, and since May 2019 he is the head of The Chair and Department of Hematology in Jagiellonian University Hospital. He has extensive clinical experience in the use of tyrosine kinase inhibitors and in the field of molecular monitoring of chronic myeloproliferative neoplasms. He is also interested in the clinical research of myeloproliferative neoplasms aiming at eliminating the leukemic stem cells.

**Valeh Huseynov**

*Hematology, Educational-Therapeutic Clinic of Azerbaijan Medical University, Azerbaijan*

**Education**

Azerbaijan Medical University 1992-1998  
Azerbaijan Medical University, Oncology Hospital, Oncology – Hematologist 1998-1999  
Oncology course on rehabilitation. Kazakhstan. Almaty. 1999  
Rehabilitation course on hematology and bone marrow transplantation. Sample education and research hospital. Turkey Ankara 2002  
Regional Blood Banking Implementation Course. Turkey. 2002

WHO training course. Quality management in the blood transfusion service. 2005

Course of Quality Standards of Cellular Therapy Products in Current/ 2015

Republic Oncology Center, Oncologist-Hematologist. Junior researcher. Kazakhstan, Almaty. 1999-2001

WHO course. Quality control during bleeding. Baku. 2005

Course at the Medical University of Vienna. Vienna, Austria. Hematology and Bone Marrow Transplantation Course. Memorial Hospital. Istanbul, Turkey. 2013

Ankara Univ., Department of Hematology, Bone Marrow Transplant Unit. Ankara. Turkey. 2014

Oncological hematology and bone marrow transplantation. Tennessee University. Memphis, USA. 2016

**WORK EXPERIENCE:**

City Oncology Dispensary, chemical therapy. Internship. Azerbaijan Baku. 1998-1999

Republic Oncology Center, Oncologist-Hematologist. Small scientific worker in Kazakhstan, Almaty. 1999-2000

Institute of Hematology and Transfusiology, Hematologist named after B. Eivazov. Scientist. Azerbaijan Baku 2000-2002

Central Clinical Hospital. Hematologist. Azerbaijan Baku. 2001-2015

Head of Hematology and Oncology Department and Blood Bank Central Clinic. Azerbaijan Baku. 2003-2009

Head of the Therapy Center. Central Clinic. Azerbaijan Baku. 2009-2012

Head of Department of Hematology at Educational-Therapeutic Clinic of Azerbaijan Medical University. Azerbaijan Baku. 2013- until now

Director of the Thalassemia Center 2017- until now

**Member Societies**

European Hematology Society (EHA)

American Hematology Society (ASH)

Chairman of the Society of Hematology Professionals of Azerbaijan.

**Vera Donnenberg**

*Cardiothoracic Surgery / Pharmaceutical Sciences, University of Pittsburgh, USA*



Dr. Vera Donnenberg is an Associate Professor of Cardiothoracic Surgery in the School of Medicine at the University of Pittsburgh with a secondary appointment in the Department of Pharmaceutical Sciences in the School of Pharmacy. She is a Representative to the Council of Faculty and Academic Societies for the Association of American Medical Colleges (CFAS-AAMC), where she is a member of the Administrative Board. She is also a Regent of the Board of the American College of Cli-

nical Pharmacology (ACCP) and serves as an Ambassador to the Eurasian Hematology Oncology Group, an international organization that promotes oncology research and clinical interventions in Europe, Asia, Africa, and Americas.

Dr. Donnenberg earned her MS in Clinical Pharmacology in 1994 from Johns Hopkins University and her PhD with Honors in Pharmaceutical Sciences in 2002 from the University of Pittsburgh.

Dr. Donnenberg's research focuses on:

- Tumorigenic stem cells in lung cancer, esophageal cancer, and breast cancer
- Pleural metastases
- Therapeutic resistance
- Interaction of tumor cells and regenerating tissue
- Lung immunology
- Pleural immuno-oncology

Dr. Donnenberg has written over 395 publications, abstracts, book chapters, and other scientific presentations. Throughout her career she has received numerous awards for her academic and service efforts including the Nathaniel Kwitt Distinguished Service Award from the ACCP (2020), the Marylou Ingram Woman in Science Award from the Coulter Foundation, the Governor's Distinguished Citizenship Award, Maryland, and the Service Award from the National Society of Black Engineers. She is a member of several editorial boards including the Journal of Clinical Pharmacology and is an Associate Editor of Cytometry, Stem Cells, a leading journal in the field of imaging and cytometry, and served as the first female President of the Great Lakes Flow Cytometry Association.

View a list of Dr. Donnenberg's publications here [[http://www.ncbi.nlm.nih.gov/pubmed?term=\(\(%22johns%20hopkins%20university%22\)%20OR%20%22university%20of%20pittsburgh%22\)%20AND%20%22donnenberg%2C%20vera%20s%22](http://www.ncbi.nlm.nih.gov/pubmed?term=((%22johns%20hopkins%20university%22)%20OR%20%22university%20of%20pittsburgh%22)%20AND%20%22donnenberg%2C%20vera%20s%22)].

**Zeba AZIZ**

*Hematology, Hameed Latif Hospital, Pakistan*



Zeba Aziz is a medical oncologist with a busy clinical practice based in Hameed Latif Hospital, Lahore, Pakistan. She previously served as the Head of Department of Oncology and Professor at Jinnah Hospital Lahore. Currently she is Dean of Medical Oncology for the College of Physicians and Surgeons Pakistan and is also the Program Director for the Medical Oncology Fellowship at Hameed Latif Hospital. She is currently the President of Society of Medical Oncology of Pakistan formed recently.

Her international efforts include being on the steering committee for the Australian & Asia Pacific Oncology Research Development (ACORD) Workshop and being an invited panelist and speaker for multiple conferences around the world. She has made contributions to research through her 79 peer-reviewed publications on Oncology. Her specific fields of interest are malignant haematology and breast cancer.